N-(2-aminoethyl)-12-methyl-12,14,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-1,3,5,7,9,11(15),13,16-octaen-16-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(2-aminoethyl)-12-methyl-12,14,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-1,3,5,7,9,11(15),13,16-octaen-16-amine
• 英文别名: N'-(12-methyl-12,14,17-triazatetracyclo[8.7.0.03,8.011,15]heptadeca-1,3,5,7,9,11(15),13,16-octaen-16-yl)ethane-1,2-diamine
• 化学式: C₁₇H₁₇N₅
• 分子量: 291.355
• InChiKey: AKFPEKVULJCIRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  68.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-碘萘-2-羧酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 sodium hydroxide 、 硫酸 、 叠氮磷酸二苯酯 、 potassium acetate 、 sodium carbonate 、 三乙胺 、 三氟乙酸 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 邻二氯苯 、 甲苯 为溶剂， 反应 116.5h， 生成 N-(2-aminoethyl)-12-methyl-12,14,17-triazatetracyclo[8.7.0.0^{3,8}.0^{11,15}]heptadeca-1,3,5,7,9,11(15),13,16-octaen-16-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors

  摘要：

  We have recently identified BMS-345541 (1) as a highly selective and potent inhibitor of IKK-2 (IC50 = 0.30 mu M), which however was considerably less potent against IKK-1 (IC50 = 4.0 mu M). In order to further explore the SAR around the imidazoquinoxaline tricyclic structure of 1, we prepared a series of tetracyclic analogues (7, 13, and 18). The synthesis and biological activities of these potent IKK inhibitors are described. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.017

文献信息

• [EN] COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY<br/>[FR] COMPOSITIONS CONTENANT UN INHIBITEUR SELECTIF DE LA CYCLOOXYGENASE-2 ET UN INHIBITEUR DES IKK, UTILISEES DANS LE TRAITEMENT DES TROUBLES OU LESIONS D'ORIGINE ISCHEMIQUE DU SYSTEME NERVEUX CENTRAL
  申请人：PHARMACIA CORP

  公开号：WO2005009354A2

  公开（公告）日：2005-02-03

  The present invention provides compositions and methods for the treatment of ischemic-mediated central nervous system disorders or injuries. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic-mediated disorder or injury comprising the administration to a subject of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor.
• Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors
  作者：Francis Beaulieu、Carl Ouellet、Edward H. Ruediger、Makonen Belema、Yuping Qiu、Xuejie Yang、Jacques Banville、James R. Burke、Kurt R. Gregor、John F. MacMaster、Alain Martel、Kim W. McIntyre、Mark A. Pattoli、F. Christopher Zusi、Dolatrai Vyas

  DOI：10.1016/j.bmcl.2006.12.017

  日期：2007.3

  We have recently identified BMS-345541 (1) as a highly selective and potent inhibitor of IKK-2 (IC50 = 0.30 mu M), which however was considerably less potent against IKK-1 (IC50 = 4.0 mu M). In order to further explore the SAR around the imidazoquinoxaline tricyclic structure of 1, we prepared a series of tetracyclic analogues (7, 13, and 18). The synthesis and biological activities of these potent IKK inhibitors are described. (c) 2006 Elsevier Ltd. All rights reserved.